Skip to main content
. 2015 Nov 14;15:517. doi: 10.1186/s12879-015-1270-8

Table 1.

Baseline characteristics of patients on second line (2nd Line) ART

Variable Number (n = 170)
Age(years) Mean ± SD 36.78 ± 7.30
Median (IQR) 35.0 (32.0-42.0)
Sex Male n (%) 141 (82.9)
Female n (%) 29 (17.1)
Duration of Immunological failure (months) Mean ± SD 17.30 ± 15.71
Median (IQR)a 12 (6.0-23.0)
Weight(Kg) at the start of 2nd line ART Mean ± SD 48.34 ± 9.07
Median (IQR)a 49.0 (41–55)
Clinical Stage at the start of 2nd line ART I + II n (%) 118 (69.4)
III + IV n (%) 52 (30.6)
CD4 count at the start of 2nd line ART (/μL) Mean ± SD 94.36 ± 72.98
Median (IQR)a 78.50 (49.75-121.25)
Viralload baseline (copies/ml) Mean ± SD 490000.00 ± 1150000.00
Median (IQR)a 1770000 (67375–3540000)
Last NRTI regimen Stavudine n (%) 81 (47.6)
Zidovudine n (%) 89 (52.4)
Total Duration of 2nd line ART (months) Mean ± SD 26.65 ± 16.76
Median (IQR)a 22.50 (14–40.25)
Tuberculosis during 1st line ART Yes n (%) 89 (52.4)
No n (%) 81 (47.6)
Tuberculosis during 2nd line ART Yes n (%) 33 (19.4)
No n (%) 137 (80.6)
1st line ART Adherence Adherence (<80-95 % ) n (%) 46 (27.1)
Adherence (>95 %) n (%) 124 (72.9)
2nd line ART Adherence Adherence (<80 %-95 %) n (%) 38 (22.4)
Adherence (>95 %) n (%) 132 (77.6)

aInter quartile range